Zevra Therapeutics, Inc. (ZVRA) Key Metrics
ZVRA valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $590.3M
- Enterprise value
- $451.6M
- P/E (TTM)
- 10.8
- Forward P/E
- 10.7
- PEG ratio
- 10.67
- Price / sales
- 4.3 10-yr median 9.0
- Price / book
- 3.1 10-yr median 3.3
- EV / EBITDA
- 5.9
- Dividend yield
- —
- Beta
- 0.98
ZVRA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsZVRA valuation Price multiples at each fiscal year-end price.
ZVRA returns How much profit the business earns on the capital it uses.
ZVRA per-share figures Results divided by the shares outstanding at year-end.
ZVRA financial health Debt, liquidity and how easily interest is covered.
ZVRA efficiency & capital use Working capital cycle and where the cash goes.
ZVRA valuation history
ZVRA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ZVRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ZVRA cash returned to shareholders
ZVRA price vs earnings per share
ZVRA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $513.1M | $385.7M | $232.2M | $158.3M | $259.3M | — | — | — | — | — |
| Enterprise value | $385.3M | $376.5M | $208.2M | $94.2M | $148.5M | — | — | — | — | — |
| P/E ratio | 6.2 | — | — | — | — | — | — | — | — | — |
| Price / sales | 4.8 | 16.3 | 8.5 | 15.6 | 9.0 | — | — | — | — | — |
| Price / book | 3.3 | 9.7 | 3.8 | 2.1 | 2.0 | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | 25.1 | — | — | — | — | — |
| Price / operating cash flow | — | — | — | — | 24.8 | — | — | — | — | — |
| EV / sales | 3.6 | 15.9 | 7.6 | 9.3 | 5.2 | — | — | — | — | — |
| EV / EBITDA | 3.9 | — | — | — | — | — | — | — | — | — |
| EV / free cash flow | — | — | — | — | 14.4 | — | — | — | — | — |
| Earnings yield | 16.2% | −27.4% | −19.8% | −16.9% | −3.3% | — | — | — | — | — |
| Free cash flow yield | −0.5% | −18.1% | −14.6% | −11.9% | 4.0% | — | — | — | — | — |
| Dividend yield | — | — | — | 0.2% | 11.9% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | 1.5% | 3.2% | 13.0% | — | — | — | — | — |
| Share price at fiscal year-end | $8.96 | $8.34 | $6.55 | $4.59 | $8.71 | $11.20 | $6.06 | $28.48 | $64.80 | $47.20 |
| Per share | ||||||||||
| Revenue per share | $1.86 | $0.51 | $0.77 | $0.29 | $0.96 | — | — | — | — | — |
| Earnings per share | $1.45 | −$2.28 | −$1.30 | −$0.78 | −$0.29 | — | — | — | — | — |
| Operating cash flow per share | −$0.03 | −$1.51 | −$0.95 | −$0.54 | $0.35 | — | — | — | — | — |
| Free cash flow per share | −$0.04 | −$1.51 | −$0.95 | −$0.55 | $0.35 | — | — | — | — | — |
| Cash per share | $3.34 | $1.50 | $1.91 | $2.40 | $3.77 | — | — | — | — | — |
| Book value per share | $2.70 | $0.86 | $1.74 | $2.18 | $4.27 | — | — | — | — | — |
| Tangible book value per share | $2.51 | −$0.74 | −$0.34 | $2.18 | $4.27 | — | — | — | — | — |
| Dividends per share | — | — | — | $0.01 | $1.04 | — | — | — | — | — |
| Capex per share | $0.01 | $0.00 | $0.01 | $0.00 | $0.00 | — | — | — | — | — |
| Debt per share | $1.10 | $1.30 | $1.23 | $0.54 | $0.05 | — | — | — | — | — |
| Shares outstanding | 57.3M | 46.3M | 35.5M | 34.5M | 29.8M | — | — | — | — | — |
| Change in shares outstanding | +23.8% | +30.5% | +2.8% | +15.9% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 85.7% | −207.8% | −67.2% | −26.5% | −28.2% | — | — | — | — | — |
| Return on invested capital (ROIC) | −14.2% | −201.1% | −160.1% | −245.2% | 74.9% | — | — | — | — | — |
| Return on assets (ROA) | 36.0% | −60.2% | −32.0% | −21.6% | −11.9% | −117.5% | −131.7% | −142.6% | −63.2% | −23.5% |
| Return on tangible assets | 30.4% | −101.0% | −46.8% | −23.2% | −6.4% | −113.8% | −233.4% | −211.1% | −82.7% | −19.5% |
| Free cash flow margin | −2.3% | −295.0% | −123.2% | −185.1% | 36.1% | −14.8% | −185.1% | — | — | — |
| Income quality (OCF / net income) | −0.02 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $63.2M | $60.3M | $43.8M | $18.8M | $1.6M | $70.5M | $79.5M | $82.0M | $93.5M | $92.0M |
| Cash & short-term investments | $191.0M | $69.5M | $67.7M | $82.8M | $112.3M | $4.2M | $3.2M | $21.7M | $42.2M | $67.8M |
| Net debt | −$127.8M | −$9.2M | −$24.0M | −$64.1M | −$110.7M | $66.3M | $76.3M | $60.4M | $51.3M | $24.2M |
| Debt / equity | 0.41 | 1.52 | 0.71 | 0.25 | 0.01 | — | — | — | — | — |
| Debt / assets | 0.22 | 0.34 | 0.25 | 0.16 | 0.01 | 6.29 | 7.57 | 3.07 | 1.78 | 1.08 |
| Net debt / EBITDA | −1.29 | — | — | — | — | — | — | — | — | — |
| Current ratio | 5.68 | 2.53 | 1.18 | 7.72 | 27.20 | 1.11 | 1.28 | 1.98 | 3.99 | 11.19 |
| Quick ratio | 5.63 | 2.47 | 0.85 | 7.72 | 27.20 | 1.10 | 1.28 | 1.96 | 3.99 | 11.03 |
| Interest coverage | -0.5 | -11.8 | -33.0 | -127.1 | 20.6 | -0.8 | -3.1 | -7.9 | -4.5 | -5.3 |
| Working capital | $183.7M | $52.0M | $13.2M | $80.8M | $110.8M | $846,000 | $1.5M | $11.7M | $34.4M | $67.7M |
| Invested capital | $26.9M | $30.5M | $37.9M | $11.1M | $16.4M | −$78,000 | $1.9M | −$6.2M | −$6.3M | $5.5M |
| Tangible asset value | $143.5M | −$34.0M | −$12.1M | $75.1M | $127.1M | −$66.4M | −$74.5M | −$66.6M | −$57.5M | −$18.7M |
| Net current asset value | $92.9M | −$52.4M | −$23.5M | $52.6M | $109.2M | −$69.2M | −$78.0M | −$69.6M | −$64.1M | −$29.2M |
| Graham number | $9.40 | — | — | — | — | — | — | — | — | — |
| Graham net-net per share | $1.38 | −$1.30 | −$0.50 | $1.42 | $3.62 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $324,000 | $30.8M | — | — | — | — | — |
| Share buybacks (net) | — | $0 | $3.4M | $4.7M | $2.8M | $0 | — | — | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | 325.4% | — | — | — | — | — |
| Capex / revenue | 0.8% | 0.0% | 1.1% | 0.9% | 0.4% | 0.2% | 0.2% | — | — | — |
| Capex / operating cash flow | — | — | — | — | 1.0% | — | — | — | — | — |
| Capex / depreciation | 0.21 | 0.00 | 0.29 | 0.10 | 0.40 | 0.12 | 0.09 | 0.06 | 0.54 | 3.67 |
| Stock-based compensation / revenue | 11.9% | 63.1% | 21.7% | 42.3% | 8.5% | 18.7% | 34.3% | — | — | — |
| R&D / revenue | 12.0% | 178.3% | 145.0% | 194.9% | 35.5% | 66.5% | 151.2% | — | — | — |
| SG&A / revenue | 72.9% | 232.4% | 90.1% | 154.0% | 30.4% | 59.6% | 84.2% | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 57.9 | 215.5 | 170.6 | 176.5 | 26.2 | 61.0 | 28.5 | — | — | — |
| Days of inventory on hand | 41.1 | 641.0 | 2,984.7 | — | 9.7 | 30.5 | — | 126.2 | 597.5 | -1,329.6 |
| Days payables outstanding | 172.2 | 665.9 | 1,090.5 | 3,392.7 | 149.8 | 323.6 | 300.9 | 3,318.8 | 1,437.2 | 1,794.8 |
| Cash conversion cycle (days) | -73.3 | 190.7 | 2,064.8 | -3,216.2 | -114.0 | -232.1 | -272.4 | — | — | — |
| Receivables turnover | 6.31 | 1.69 | 2.14 | 2.07 | 13.95 | 5.98 | 12.81 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 2.12 | 0.55 | 0.33 | 0.11 | 2.44 | 1.13 | 1.21 | 0.11 | 0.25 | 0.20 |
| Inventory turnover | 8.89 | 0.57 | 0.12 | — | 37.78 | 11.97 | — | 2.89 | 0.61 | — |
| Asset turnover | 0.46 | 0.13 | 0.19 | 0.08 | 0.40 | 1.22 | 0.69 | 0.00 | 0.00 | 0.00 |
| Average receivables | $16.9M | $13.9M | $12.8M | $4.9M | $2.1M | $2.2M | $1.0M | $1.1M | $3.6M | $3.7M |
| Average payables | $7.8M | $13.5M | $8.8M | $2.1M | $845,000 | $1.2M | $2.4M | $2.9M | $1.3M | $860,500 |
| Average inventory | $1.9M | $13.0M | $24.1M | — | $54,500 | $109,000 | — | $112,000 | $550,000 | −$637,500 |
| Intangibles / total assets | 3.9% | 41.4% | 42.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ZVRA's annual financial statements (latest annual report filed March 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ZVRA valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Zevra Therapeutics traded at 6.2 times earnings. Based on the latest twelve months, the trailing P/E is 10.8 and the forward P/E is 10.7. Zevra Therapeutics earned a return on equity of 85.7% and a return on invested capital of −14.2% in fiscal 2025. It ended the year with $63.2 million of debt and $191.0 million in cash and short-term investments, a net cash position of $127.8 million.
See the ZVRA income statement, the ZVRA chart for price history, or the ZVRA stock overview for the latest quote and news.
ZVRA key metrics FAQ
What is Zevra Therapeutics's P/E ratio?
Zevra Therapeutics's trailing P/E ratio is 10.8 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 10.7. At the end of fiscal 2025 it was 6.2.
What is Zevra Therapeutics's EV/EBITDA?
Zevra Therapeutics's enterprise value was 3.9 times EBITDA at the end of fiscal 2025 (enterprise value $385.3 million, EBITDA $98.7 million); the current EV/EBITDA is 5.9.
What is Zevra Therapeutics's return on equity?
Zevra Therapeutics's return on equity (ROE) was 85.7% in fiscal 2025: net income of $83.2 million on average shareholders' equity of $97.2 million.
What is Zevra Therapeutics's ROIC?
Zevra Therapeutics's return on invested capital was −14.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Zevra Therapeutics have?
Zevra Therapeutics had total debt of $63.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.41 and more cash than debt.
What is Zevra Therapeutics's free cash flow yield?
Zevra Therapeutics generated -$2.4 million of free cash flow in fiscal 2025, a free cash flow yield of −0.5% on its market value at year-end ($513.1 million).
What is Zevra Therapeutics's current ratio?
Zevra Therapeutics's current ratio was 5.68 at the end of fiscal 2025: current assets were 5.68 times current liabilities.